135 related articles for article (PubMed ID: 11673753)
1. A population pharmacokinetic-pharmacodynamic analysis and model validation of azimilide.
Phillips L; Grasela TH; Agnew JR; Ludwig EA; Thompson GA
Clin Pharmacol Ther; 2001 Oct; 70(4):370-83. PubMed ID: 11673753
[TBL] [Abstract][Full Text] [Related]
2. Effects of azimilide on heart rate and ECG conduction intervals during sinus rhythm in patients with a history of atrial fibrillation.
Pritchett EL; Schulte MC; Schnell D; Marcello SR; Wilkinson WE; Page RL; Connolly SJ;
J Clin Pharmacol; 2002 Apr; 42(4):388-94. PubMed ID: 11936563
[TBL] [Abstract][Full Text] [Related]
3. Influence of coadministration on the pharmacokinetics of azimilide dihydrochloride and digoxin.
Toothaker RD; Corey AE; Valentine SN; Agnew JR; Parekh N; Moehrke W; Thompson GA; Powell JH
J Clin Pharmacol; 2005 Jul; 45(7):773-80. PubMed ID: 15951467
[TBL] [Abstract][Full Text] [Related]
4. Azimilide dihydrochloride, a novel antiarrhythmic agent.
Karam R; Marcello S; Brooks RR; Corey AE; Moore A
Am J Cardiol; 1998 Mar; 81(6A):40D-46D. PubMed ID: 9537222
[TBL] [Abstract][Full Text] [Related]
5. Azimilide.
Clemett D; Markham A
Drugs; 2000 Feb; 59(2):271-7; discussion 278-9. PubMed ID: 10730550
[TBL] [Abstract][Full Text] [Related]
6. Azimilide pharmacokinetics following intravenous and oral administration of a solution and capsule formulation.
Corey AE; Agnew JR; Valentine SN; Nesbitt JD; Wagner DL; Powell JH; Thompson GA
J Clin Pharmacol; 1999 Dec; 39(12):1272-6. PubMed ID: 10586393
[TBL] [Abstract][Full Text] [Related]
7. Effects of intravenous azimilide on cardiac performance, fibrillation threshold, and hemodynamics in anesthetized dogs.
Brooks RR; Finch SL
Arzneimittelforschung; 2000 Jul; 50(7):597-605. PubMed ID: 10965415
[TBL] [Abstract][Full Text] [Related]
8. Azimilide pharmacokinetics and pharmacodynamics upon multiple oral dosing.
Corey A; Al-Khalidi H; Brezovic C; Marcello S; Parekh N; Taylor K; Karam R
Biopharm Drug Dispos; 1999 Mar; 20(2):59-68. PubMed ID: 10206320
[TBL] [Abstract][Full Text] [Related]
9. Influence of azimilide on CYP2C19-mediated metabolism.
El Mouelhi M; Worley DJ; Kuzmak B; Destefano AJ; Thompson GA
J Clin Pharmacol; 2004 Apr; 44(4):373-8. PubMed ID: 15051744
[TBL] [Abstract][Full Text] [Related]
10. Azimilide dihydrochloride: a new class III anti-arrhythmic agent.
Abrol R; Page RL
Expert Opin Investig Drugs; 2000 Nov; 9(11):2705-15. PubMed ID: 11060832
[TBL] [Abstract][Full Text] [Related]
11. Influence of ketoconazole on azimilide pharmacokinetics in healthy subjects.
El Mouelhi M; Worley DJ; Kuzmak B; Destefano AJ; Thompson GA
Br J Clin Pharmacol; 2004 Dec; 58(6):641-7. PubMed ID: 15563362
[TBL] [Abstract][Full Text] [Related]
12. Azimilide dihydrochloride: a unique class III antiarrhythmic agent.
Tran HT
Heart Dis; 1999; 1(2):114-6. PubMed ID: 11720612
[TBL] [Abstract][Full Text] [Related]
13. The effect of isoproterenol on the class III effect of azimilide in humans.
Dorian P; Dunnmon P; Elstun L; Newman D
J Cardiovasc Pharmacol Ther; 2002 Oct; 7(4):211-7. PubMed ID: 12490966
[TBL] [Abstract][Full Text] [Related]
14. The azimilide post-infarct survival evaluation (ALIVE) trial.
Camm AJ; Karam R; Pratt CM
Am J Cardiol; 1998 Mar; 81(6A):35D-39D. PubMed ID: 9537221
[TBL] [Abstract][Full Text] [Related]
15. Antiarrhythmic effects of azimilide in paroxysmal supraventricular tachycardia: efficacy and dose-response.
Page RL; Connolly SJ; Wilkinson WE; Marcello SR; Schnell DJ; Pritchett EL;
Am Heart J; 2002 Apr; 143(4):643-9. PubMed ID: 11923801
[TBL] [Abstract][Full Text] [Related]
16. Effect of severe renal impairment on the pharmacokinetics of azimilide following single dose oral administration.
Corey AE; Agnew JR; Valentine SN; Parekh NJ; Powell JH; Thompson GA
Br J Clin Pharmacol; 2002 Nov; 54(5):449-52. PubMed ID: 12445022
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and pharmacodynamics following intravenous doses of azimilide dihydrochloride.
Corey A; Agnew J; Brum J; Parekh N; Valentine S; Williams M
J Clin Pharmacol; 1999 Dec; 39(12):1263-71. PubMed ID: 10586392
[TBL] [Abstract][Full Text] [Related]
18. Cumulative experience of azimilide-associated torsades de pointes ventricular tachycardia in the 19 clinical studies comprising the azimilide database.
Pratt CM; Al-Khalidi HR; Brum JM; Holroyde MJ; Schwartz PJ; Marcello SR; Borggrefe M; Dorian P; Camm AJ;
J Am Coll Cardiol; 2006 Aug; 48(3):471-7. PubMed ID: 16875971
[TBL] [Abstract][Full Text] [Related]
19. The class III effect of azimilide is not associated with reverse use-dependence in open-chest dogs.
Qi XQ; Newman D; Dorian P
J Cardiovasc Pharmacol; 1999 Dec; 34(6):898-903. PubMed ID: 10598136
[TBL] [Abstract][Full Text] [Related]
20. Symptoms at the time of arrhythmia recurrence in patients receiving azimilide for control of atrial fibrillation or flutter: results from randomized trials.
Connolly SJ; Schnell DJ; Page RL; Wilkinson WE; Marcello SR; Pritchett EL;
Am Heart J; 2003 Sep; 146(3):489-93. PubMed ID: 12947368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
